Truist Securities Maintains Hold on Integra Lifesciences, Raises Price Target to $44
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Richard Newitter has maintained a Hold rating on Integra Lifesciences (NASDAQ:IART) and increased the price target from $39 to $44.
December 14, 2023 | 6:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities reaffirmed a Hold rating on Integra Lifesciences while raising the price target from $39 to $44, indicating a positive outlook on the stock's value.
The increase in price target by Truist Securities suggests an improved outlook on Integra Lifesciences' valuation, which could lead to positive investor sentiment and a potential increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100